Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.43 |
| ▸ | LDHA | P00338 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578096 | 0.98 | KDM4E (0.46) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| Ethylene SCHEMBL27344274 | 0.96 | KDM4E (0.44) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL27830260 | 0.86 | ALDH1A1 (0.35) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL9568954 | 0.85 | L3MBTL1 (0.42) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL27830221 | 0.83 | KDM4E (0.35) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL6844961 | 0.82 | CBLB (0.35) | KDM4EALDH1A1GAASMN1; SMN2LDHA | |
| SCHEMBL15356473 | 0.82 | KDM1A (0.41) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL3262633 | 0.82 | HTR2B (0.44) | KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL27344272 | 0.82 | ALDH1A1 (0.34) | KDM4EALDH1A1GAASMN1; SMN2L3MBTL1 | |
| Lithium Ion SCHEMBL578095 | 0.81 | PTGER1 (0.36) | KDM4EALDH1A1GAASMN1; SMN2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102137851-B | Compound as vanilloid receptor antagonist, isomer thereof or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising same | AMOREPACIFIC CORP | 2014-08-27 | — | — | CN | claimed |
| CN-102421760-A | Dihydropyrimidinones useful as BACE2 inhibitors | HOFFMANN LA ROCHE | 2012-04-18 | — | — | CN | claimed |
| CN-102137851-A | Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same | AMOREPACIFIC CORP | 2011-07-27 | — | — | CN | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565498-B2 | β-lactamase inhibitors and their preparation | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2026-03-03 | — | — | US | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | CELLARITY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| CN-120058672-A | Halogenated pyridylcarboxylic acid ester derivative and application thereof | 贵州医科大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-1836203-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006122200-A1 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006120481-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-0402246-B1 | Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation | ROUSSEL UCLAF (FR) | 1994-08-24 | — | — | EP | disclosed |
| US-5136042-A | PROCESS FOR THE PREPARATION OF THIAZOLECARBOXYLIC ACID CHLORIDES | MITSUI TOATSU CHEMICALS, INC. (JP) | 1992-08-04 | — | — | US | disclosed |
| EP-0402246-A1 | Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation | ROUSSEL-UCLAF (FR) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | KDM4E 659/4885ALDH1A1 621/4885GAA 133/4885 |
| US-12565498-B2 | β-lactamase inhibitors and their preparation | PGLS, MGAM, OSTC | KDM4E 2288/4885ALDH1A1 452/4885GAA 119/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885GAA 1755/4885 |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | KDM4E 4324/4885ALDH1A1 847/4885GAA 2372/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | KDM4E 2548/4885ALDH1A1 563/4885GAA 39/4885 |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | KDM4E 4324/4885ALDH1A1 847/4885GAA 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.